The Finished Dosage Formulations business includes the manufacture and marketing of generics formulations products. We are aggressively expanding our presence in Europe, Canada, Australia and Japan. We are also rapidly expanding in Rest of the World (RoW) markets like Asia, Middle East, Latin America and Africa.

The business derives benefit of backward integration with majority of our commercial Solid Dosage Formulations backward integrated to in-house APIs. This helps us to ensure quality right from the basic stage, besides reduction in the costs and maintaining optimal efficiency.

In R&D, we have more than 450 experienced scientists constantly focusing on innovation and building up the pipeline of newer products. We specialise in key complex technologies like MUPS, Chew Tabs, Oro-dissolving Tablets, POS, Double layered tablets, etc.

Our current & future portfolio is focused on fast growing therapy segments like Cardiovascular, Antidiabetics, Central Nervous System, Anti-infective, etc. We have more than 40+ key products in these segments which are currently at different stages of development and would be available in next couple of years for filings.